Small Positive
• Wins a 3 year reprieve from Section 232 Tariffs.
• Agreed to provide Direct-to-Consumer sales at up to 80% discount to list price for eligible patients.
• Will sales via the TrumpRx platform.
• Already agreed to invest $50bn in US Manufacturing and R&D. This is not new.
IR Link
Find more articles and bullets on these widgets:
Aussie 3-yr futures are trading off recent lows. A resumption of gains from here would further narrow the gap with resistance at 96.730, the Sep 17 ‘24 high, leaving 96.860 as the next key level. Any continuation lower would instead strengthen a bearish threat. This would refocus attention on 95.760, the 14 Nov ‘24 low. Conversely, a reversal higher would open 96.860, the Apr 7 high.
We've published our preview of the upcoming FOMC meeting - Download Full Report Here
MNI’s separate preview of sell-side analyst summaries to follow on Monday Sep 15

Fitch has downgraded France's sovereign rating to A+ (with stable outlook) from AA-. Release here.